Oncternal Therapeutics Inc logo

Oncternal Therapeutics Inc (ONCT) live share price

Oncternal Therapeutics Inc share price in USD $0.69 & INR ₹58.33

$0.69

-0.05

(-7.16%)

View live Oncternal Therapeutics Inc share price in Dollar and Rupees. Guide to invest in Oncternal Therapeutics Inc from India. Also see the sentimental analysis on Indian investors investing in Oncternal Therapeutics Inc. Get details on the Indian mutual funds that are investing in Oncternal Therapeutics Inc. Get Analyst recommendations and forecasts along with all the Oncternal Therapeutics Inc's financials.

Oncternal Therapeutics Inc share price movements

  • $0.66
    $0.74

    Day's Volatility :10.55%

  • $0.62
    $13.14

    52 Weeks Volatility :95.28%

Oncternal Therapeutics Inc Returns

PeriodOncternal Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-83.03%
-6.2%
0.0%
6 Months
-92.1%
2.6%
0.0%
1 Year
-89.94%
11.8%
0.0%
3 Years
-98.79%
13.8%
-17.6%

Oncternal Therapeutics Inc Key Statistics

in dollars & INR

Market Capitalization
$3.3M
Revenue TTM
$2.2M
Earnings Per Share (EPS)
$-11.39
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-149.86%

How to invest in Oncternal Therapeutics Inc from India?

It is very easy for Indian residents to invest directly in Oncternal Therapeutics Inc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Oncternal Therapeutics Inc stock in both rupees (INR) and dollars (USD). Search for Oncternal Therapeutics Inc or ONCT on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Oncternal Therapeutics Inc or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Oncternal Therapeutics Inc shares which would translate to 1.225 fractional shares of Oncternal Therapeutics Inc as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Oncternal Therapeutics Inc

62.5%

Period: Sep 1, 2024 to Nov 30, 2024. Change in 30 Days versus previous period

Investment in Oncternal Therapeutics Inc from India has grown in the last 30 days as on Dec 1, 2024. 62.5% more purchase transactions for Oncternal Therapeutics Inc in the last 30 days versus the previous period.

39%

Period: Sep 1, 2024 to Nov 30, 2024. Change in 30 Days versus previous period

Search volume for Oncternal Therapeutics Inc on INDmoney from India has grown in the last 30 days as on Dec 1, 2024. 39% more investors are searching Oncternal Therapeutics Inc in the last 30 days versus the previous period.

Global Institutional Holdings in Oncternal Therapeutics Inc

  • Vanguard Group Inc

    4.83%

  • Millennium Management LLC

    3.48%

  • BlackRock Inc

    1.33%

  • Morgan Stanley - Brokerage Accounts

    1.02%

  • Dimensional Fund Advisors, Inc.

    0.89%

  • Geode Capital Management, LLC

    0.87%

Analyst Recommendation on Oncternal Therapeutics Inc

Buy

    80%Buy

    20%Hold

    0%Sell

Based on 10 Wall street analysts offering stock ratings for Oncternal Therapeutics Inc(by analysts ranked 0 to 5 stars)

Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
2
2
2
Sell
0
0
0

Analyst Forecast on Oncternal Therapeutics Inc

What analysts predicted

Upside of 189.86%

Current:

$0.69

Target:

$2.00

Insights on Oncternal Therapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 5 quarters, 106.0K → 801.0K (in $), with an average increase of 39.3% per quarter
  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -8.55M → -8.46M (in $), with an average increase of 1.1% per quarter
  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 47.6% return, outperforming this stock by 137.5%
  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 40.6% return, outperforming this stock by 139.4%

Oncternal Therapeutics Inc Technicals Summary

Sell

Neutral

Buy

Oncternal Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Oncternal Therapeutics Inc Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Oncternal Therapeutics Inc
-53.74%
-92.1%
-89.94%
-98.79%
-99.33%
Regeneron Pharmaceuticals, Inc.
-11.07%
-24.18%
-8.88%
18.33%
103.42%
Biontech Se
6.2%
15.09%
18.5%
-64.5%
470.0%
Alnylam Pharmaceuticals, Inc.
-7.61%
68.21%
46.39%
38.4%
106.81%
Vertex Pharmaceuticals Incorporated
-0.63%
-0.44%
33.51%
128.97%
111.7%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Oncternal Therapeutics Inc
NA
NA
NA
-11.88
-1.5
-0.76
NA
3.09
Regeneron Pharmaceuticals, Inc.
18.66
18.66
1.12
44.91
0.17
0.07
NA
272.04
Biontech Se
160.8
NA
0.04
-3.06
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
32.84
NA
1.22
0.54
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Oncternal Therapeutics Inc
Buy
$3.3M
-99.33%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Buy
$83.0B
103.42%
18.66
33.61%
Biontech Se
Buy
$28.9B
470.0%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Buy
$32.7B
106.81%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Buy
$119.6B
111.7%
32.84
-4.51%

About Oncternal Therapeutics Inc

oncternal therapeutics, inc., a clinical-stage biopharmaceutical company, develops oncology therapies for the treatment of cancers with critical unmet medical need. the company's product pipeline include cirmtuzumab, a monoclonal antibody designed to inhibit the receptor-tyrosine kinase-like orphan receptor 1 (ror1) that is in phase i/ii clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia; and is in phase ib clinical trial in combination with paclitaxel for the treatment of women with human epidermal growth factor receptor 2-negative metastatic or breast cancer. it also develops tk-216, a small-molecule that is designed to inhibit e26 transformation specific family of oncoproteins, which is in phase i clinical trial to treat patients with ewing sarcoma and in combination with vincristine chemotherapy. in addition, the company develops a chimeric antigen receptor-t product candidate that targets ror1, whic
Organization
Oncternal Therapeutics Inc
Employees
27
CEO
Dr. James B. Breitmeyer M.D., Ph.D.
Industry
Biotechnology

Important FAQs about investing in Oncternal Therapeutics Inc from India :

What is Oncternal Therapeutics Inc share price today?

Oncternal Therapeutics Inc (ONCT) share price today is $0.69.

Can Indians buy Oncternal Therapeutics Inc shares?

Yes, Indians can invest in the Oncternal Therapeutics Inc (ONCT) from India.

With INDmoney, you can buy Oncternal Therapeutics Inc at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Oncternal Therapeutics Inc at zero transaction cost.

How can I buy Oncternal Therapeutics Inc shares from India?

It is very easy to buy Oncternal Therapeutics Inc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Oncternal Therapeutics Inc be purchased?

Yes, you can buy fractional shares of Oncternal Therapeutics Inc with INDmoney app.

What are the documents required to start investing in Oncternal Therapeutics Inc stocks?

To start investing in Oncternal Therapeutics Inc, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Oncternal Therapeutics Inc

Today’s highest price of Oncternal Therapeutics Inc (ONCT) is $0.74.

Today’s lowest price of Oncternal Therapeutics Inc (ONCT) is $0.66.

What is today's market capitalisation of Oncternal Therapeutics Inc

Today's market capitalisation of Oncternal Therapeutics Inc ONCT is 3.3M

What is the 52 Week High and Low Range of Oncternal Therapeutics Inc

  • 52 Week High

    $13.14

  • 52 Week Low

    $0.62

How much percentage Oncternal Therapeutics Inc is down from its 52 Week High?

Oncternal Therapeutics Inc (ONCT) share price is $0.69. It is down by 99% from its 52 Week High price of $13.14.

How much percentage Oncternal Therapeutics Inc is up from its 52 Week low?

Oncternal Therapeutics Inc (ONCT) share price is $0.69. It is up by 1% from its 52 Week Low price of $0.62.

What are the historical returns of Oncternal Therapeutics Inc?

  • 1 Month Returns

    -53.74%

  • 3 Months Returns

    -92.1%

  • 1 Year Returns

    -89.94%

  • 5 Years Returns

    -99.33%

Who is the Chief Executive Officer (CEO) of Oncternal Therapeutics Inc

Dr. James B. Breitmeyer M.D., Ph.D. is the current Chief Executive Officer (CEO) of Oncternal Therapeutics Inc.